TY  -  
T1  - Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma : Long-Term Results of the PRIMA Study 
SN  -  /  
UR  - http://hdl.handle.net/10138/310550 
T3  -  
A1  - Bachy, Emmanuel; Seymour, John F.; Feugier, Pierre; Offner, Fritz; Lopez-Guillermo, Armando; Belada, David; Xerri, Luc; Catalano, John V.; Brice, Pauline; Lemonnier, Francois; Martin, Alejandro; Casasnovas, Olivier; Pedersen, Lars M.; Dorvaux, Veronique; Simpson, David; Leppä, Sirpa; Gabarre, Jean; da Silva, Maria G.; Glaisner, Sylvie; Ysebaert, Loic; Vekhoff, Anne; Intragumtornchai, Tanin; Le Gouill, Steven; Lister, Andrew; Estell, Jane A.; Milone, Gustavo; Sonet, Anne; Farhi, Jonathan; Zeuner, Harald; Tilly, Herve; Salles, Gilles 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety. METHODS Patients (> 18 years of age) with previously untreated high-tumor-... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - NON-HODGKINS-LYMPHOMA; PHASE-III; RESPONSE DURATION; R-CVP; CYCLOPHOSPHAMIDE; THERAPY; CHEMOTHERAPY; VINCRISTINE; PREDNISONE; TRIAL; 3122 Cancers 
N1  -   
PP  -  
ER  -